SAB Biotherapeutics, Inc. (SABS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. SAB Biotherapeutics, Inc. (now operating as SAB BIO) is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies. The company's lead candidate, SAB-142, is a human anti-thymocyte globulin (ATG) designed to delay the progression of Type 1 Diabetes (T1D). The company recently initiated a Phase 1 trial for SAB-142 and received FDA clearance for its Investigational New Drug (IND) application in May 2024. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $263,137 | $1,207,712 | $666,619 |
| Net Loss | $(7,335,455) | $(12,361,200) | $(14,234,706) |
| Loss Per Share (Basic/Diluted) | $(0.79) | $(1.34) | $(2.82) |
| Operating Expenses | $10,464,835 | $22,800,026 | $14,545,246 |
| Cash & Cash Equivalents | $17,242,442 | $17,242,442 | $7,774,459 |
| Short-term Investments | $20,083,621 | $20,083,621 | $0 |
| Total Liquidity | $37,326,063 | $37,326,063 | $7,774,459 |
| Accumulated Deficit | $(102,424,741) | $(102,424,741) | $(62,104,461) |
Debt & Liabilities: Total liabilities were $15.8 million as of June 30, 2024, down from $26.6 million at year-end 2023. This decrease was primarily driven by a reduction in warrant liabilities from $11.8 million to $4.1 million. Current liabilities include approximately $616,000 in notes payable and $5.1 million in accrued expenses.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 207.7% quarter-over-quarter and 81.2% year-over-year (YTD). This is primarily attributed to the recognition of deferred grant income related to the termination and settlement of the JPEO Rapid Response Contract with the Department of Defense.
- Operating Expenses: Total operating expenses increased 59.4% QoQ and 56.8% YTD. Research and Development (R&D) expenses rose 86.3% QoQ and 80.2% YTD, driven by increased clinical trial costs, outside laboratory services, and salaries. General and Administrative (G&A) expenses increased 25.6% QoQ and 26.5% YTD due to higher personnel costs and professional fees.
- Non-Operating Income: The company recorded a significant gain of $7.7 million YTD from changes in the fair value of warrant liabilities, compared to a loss of $0.3 million in the prior year. This gain significantly reduced the net loss for the period.
- Liquidity Position: Cash and cash equivalents decreased by $39.3 million YTD due to operating losses and net purchases of investment securities ($20.1 million used in investing activities). However, total liquidity (cash + short-term investments) remains at $37.3 million.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. The company expects its current cash and short-term investments ($37.3 million) will not be sufficient to fund operations for more than 12 months from the date of issuance. Additional capital will be required to continue clinical development and operations.
- Clinical Outlook: The company anticipates topline results for the Phase 1 trial of SAB-142 by the end of 2024. These results are expected to support re-dosing and enable global Phase 2 clinical proof-of-concept trials.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to a material weakness in the design and operating effectiveness of the control environment regarding financial reporting documentation. Remediation efforts are underway, including engaging a third-party firm and implementing a contract management platform.
- Risk Factors: Key risks include the inability to raise additional capital on acceptable terms, potential failure of clinical trials, and the need to scale back operations if funding is not secured.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for when current liquidity ($37.3M) will be exhausted given the burn rate of ~$18.5M in operating cash outflows for the first half of 2024.
- Capital Raise Plans: Confirm if the company has initiated any equity or debt financing discussions to address the going concern warning.
- Warrant Liability Volatility: Note that the reduction in net loss was heavily influenced by a non-cash gain on warrant liabilities ($7.7M); verify the sustainability of this metric.
- Internal Control Remediation: Monitor progress on fixing the material weakness in financial reporting controls to ensure future financial data reliability.
- Grant Revenue Sustainability: Assess the likelihood of future revenue, as the recent increase was driven by a one-time contract termination settlement rather than recurring commercial sales.